But what about …
You’ve read one of our articles about why the amount we pay for branded drugs while they’re on patent is worth it, or our calls for insurance reform. But you still have some questions. We hope this answers your question, and if it doesn’t, write to us to let us know why.
Biotech’s Dulcius Ex Asperis: The Way Through This Downturn (Bionic Reading)
The biotech sector is experiencing the most severe downturn of at least the last 20 years. There have been many other downturns in the more recent past, but this one is different. Here Peter Kolchinsky discusses why - and how we’ll rebound.
Step-by-step price discovery for private companies
There is a simple process by which any board of a private company can ensure that it finds a price at which its existing investors and new ones will give it the funding it wants. Aspects of this process are relevant whether a company is heading into a private financing or preparing for an IPO. Check it out here.